Art

J-GLOBAL ID：201902219669542896   Reference number：19S0759221

Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: A cost-effectiveness analysis

Author (8)： Saito, Shota (Department of Medical Informatics and Statistics, Niigata University Graduate School of Medicine) ,  Shimizu, Utako (Department of Medical Informatics and Statistics, Niigata University Graduate School of Medicine) ,  Nan, Zhang (Department of Medical Informatics and Statistics, Niigata University Graduate School of Medicine) ,  Mandai, Nozomu (Department of Medical Informatics and Statistics, Niigata University Graduate School of Medicine) ,  Yokoyama, Junji (Department of Gastroenterology and Hepatology, Niigata University Medical and Dental Hospital) ,  Yokoyama, Junji (Department of Endoscopy, Niigata University Medical and Dental Hospital) ,  Terajima, Kenshi (Department of Medical Informatics, Niigata University Medical and Dental Hospital) ,  Akazawa, Kouhei (Department of Medical Informatics, Niigata University Medical and Dental Hospital)
Material： Journal of Crohn's and Colitis
Volume： 7  Issue： 2  Page： 167-174  Publication year： 2013 
JST Material Number： SCOPUS  ISSN： 1873-9946 
Country of issue： Netherlands (NLD)  Language： English (EN)

Terms in the title (2)： ImPACT ,  Infliximab